Printer Friendly

SillaJen expands partnership with ABL Europe for oncolytic virus therapies JX-594 & JX-970.

M2 PHARMA-January 23, 2018-SillaJen expands partnership with ABL Europe for oncolytic virus therapies JX-594 & JX-970


South Korean biotechnology company SillaJen Inc (KOSDAQ:215600) stated on Monday that it has expanded its strategic manufacturing collaboration in oncolytic virus therapies with ABL Europe, which provides viral vector GMP services for gene therapy , oncolytic products and vaccines for clinical supply.

Pursuant to the current agreement, ABL is currently manufacturing Pexa-Vec (formerly JX-594) for SillaJen's multinational, randomised Phase 3, open-label study of Pexa-Vec in patients with advanced liver cancer.

The Pexa-Vec vaccinia strain naturally targets cancer cells due to common genetic defects in cancer cells. Pexa-Vec is engineered to express the immunogenic GM-CSF protein, which complements the cancer cell lysis of the product candidate, leading to tumor necrosis, tumor vasculature shutdown and sustained anti-tumoral immune attack. The ongoing Phase 3 PHOCUS trial is designed to enroll 600 patients who have not received prior systemic treatment for their cancer.

As part of the expanded agreement, ABL will provide development, manufacturing & QC release testing services for SillaJen's pipeline product, JX-970.

According to the company, JX-970 is an oncolytic virus that is derived from a Western Reserve strain vaccinia virus and its tumor selectivity has been optimized through deletion of thymidine kinase (TK) and vaccinia growth factor (VGF). In addition, it expresses GM-CSF to stimulate immune responses.

((Comments on this story may be sent to

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jan 23, 2018
Previous Article:Water Street & medical partner awarded US FDA approval for Bivalirudin in first frozen premixed ready-to-use formulation presentation.
Next Article:AnGes seeks PDMA marketing approval for HGF gene therapy for CLI.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters